ABVC BIOPHARMA, INC. (ABVC) - Dilution Analysis

10-Q filing | 25.4M shares outstanding

POS AM filing: This prospectus relates to the offer and sale of up to 225,500 shares of common stock underlying warrants previously issued by ABVC Biopharma, Inc.

10-Q filing | 19.5M shares outstanding

POS AM filing: This prospectus relates to the resale of up to 1,000,000 shares of Common Stock underlying a common stock purchase warrant by the selling stockholders.

POS AM filing: This is a POS AM filing for common stock being offered by Selling Stockholders, up to 3,400,187 shares, at prevailing market prices or privately negotiated prices. The company will not receive any proceeds from the sales.

POS AM filing: This is a filing for shares of common stock issuable upon exercise of outstanding warrants.

S-3 filing: ABVC BioPharma, Inc. may offer and sell common stock, preferred stock, warrants, or a combination of these securities, or units, for an aggregate offering price of up to $100,000,000.

POS AM filing: This is a POS AM filing for ABVC BioPharma, Inc. relating to the offering of up to 11,714,683 shares of common stock by selling stockholders, including shares issuable upon conversion of notes and warrants.

POS AM filing: This is a filing for up to 11,714,683 shares of common stock by selling stockholders.

10-Q filing | 16.8M shares outstanding

8-K filing: The company sold 724,372 shares of its common stock to 15 Non-U.S. Persons for aggregate gross proceeds of approximately $436,000. ($0.44M proceeds)

10-K filing | 15.8M shares outstanding

8-K filing: ABVC BioPharma, Inc. entered into a third letter agreement with Lind Global Fund II, LP, pursuant to which Lind agreed to exercise for cash 1,029,167 of the Existing Warrants to purchase shares of Common Stock at a reduced exercise price of $0.40 per share. ($0.41M proceeds)

10-Q filing | 12.4M shares outstanding

8-K filing: ABVC BioPharma, Inc. entered into a letter agreement with Lind Global Fund II, LP, pursuant to which Lind agreed to exercise, for cash, 500,000 of the Existing Warrants to purchase shares of Common Stock at a reduced exercise price of $0.42 per share. ($0.21M proceeds)

10-Q filing | 11.3M shares outstanding

POS AM filing: This POS AM filing relates to an offering of up to 3,400,187 shares of Common Stock by Selling Stockholders. The Selling Stockholders may sell their shares at prevailing market prices or privately negotiated prices. The company will not receive any proceeds from the sales.

S-1 filing: This prospectus relates to the resale of up to 1,000,000 shares of Common Stock underlying a common stock purchase warrant by the selling stockholders.

8-K filing: ABVC entered into a definitive agreement with OncoX BioPharma, Inc., granting OncoX an exclusive right to develop and commercialize ABVC's BLEX 404 botanical drug for treatment of Myelodysplastic Syndrome in a specified territory for 20 years, in exchange for $6,250,000 (or 1,250,000 Oncox shares valued at $5 per share) and additional milestone payments and royalties. ($6.25M proceeds)

8-K filing: ABVC BioPharma, Inc. entered into a letter agreement with Lind Global Fund II, LP, pursuant to which Lind will exercise 1,000,000 Existing Warrants to purchase shares of Common Stock at a reduced exercise price of $0.75 per share and receive a new warrant to purchase 1,000,000 shares of Common Stock at $1.00 per share. ($0.75M proceeds)

10-Q filing | 10.9M shares outstanding

8-K filing: ABVC entered into a definitive agreement with OncoX BioPharma, Inc. to grant OncoX an exclusive right to develop and commercialize ABVC's BLEX 404 for treatment of Tripple Negative Breast Cancer in a certain territory for 20 years, in consideration of $6,250,000 (or 1,250,000 Oncox shares valued at $5 per share) and royalties. ($6.25M proceeds)

8-K filing: ABVC entered into a definitive agreement with OncoX BioPharma, Inc., granting Oncox an exclusive right to develop and commercialize ABVC's BLEX 404 for the treatment of Pancreatic Cancer in a specified territory, in consideration for $6,250,000 (or 1,250,000 Oncox shares valued at $5 per share) and future royalties. ($6.25M proceeds)

POS AM filing: This is a POS AM filing detailing the offering of shares of common stock issuable upon exercise of outstanding warrants from a previous offering.

8-K filing: ABVC entered into a definitive agreement with OncoX BioPharma, Inc. granting Oncox an exclusive right to develop and commercialize ABVC's botanical drug for Non-Small Cell Lung Cancer within North America for 20 years, in exchange for $6,250,000 (or 1,250,000 Oncox shares valued at $5 per share) and royalties. ($6.25M proceeds)

8-K filing: The Company and BIOFIRST CORPORATION entered into a licensing agreement with ForSeeCon Eye Corporation (FEYE) for the products in their Ophthalmology pipeline, including Vitargus, with the potential for payment in FEYE stock. ($30.0M proceeds)

S-1/A filing: This S-1/A filing includes information on other expenses of issuance and distribution, indemnification of directors and officers, recent sales of unregistered securities, and exhibits and financial statement schedules.

10-K filing | 10.6M shares outstanding

S-1/A filing: This prospectus relates to the resale of common stock by selling stockholders.

S-1/A filing: This prospectus relates to the resale of up to 11,714,683 shares of Common Stock by the selling stockholders.

8-K filing: ABVC BioPharma, Inc. entered into a definitive agreement with Shuling Jiang to acquire land in exchange for 703,495 restricted shares of common stock at $3.50 per share and warrants to purchase up to 1,000,000 shares at $2.00 per share. ($2.46M proceeds)

8-K filing: ABVC BioPharma, Inc. entered into a securities purchase agreement with Lind Global Fund II, LP, issuing a secured, convertible note in the principal amount of $1,000,000 for a purchase price of $833,333, convertible into common stock, and a warrant to purchase up to 1,000,000 shares of common stock.

S-1 filing: This prospectus relates to the resale, from time to time, by the selling stockholders of up to 10,403,969 shares of Common Stock of ABVC BioPharma, Inc.

8-K filing: ABVC BioPharma, Inc. entered into a securities purchase agreement with Lind Global Fund II, LP, issuing a secured, convertible note in the principal amount of $1,200,000 for a purchase price of $1,000,000, convertible into common stock, and a warrant to purchase up to 1,000,000 shares of common stock.

8-K filing: ABVC and its subsidiary BioLite entered into global licensing agreements with AiBtl BioPharma Inc. (AIBL), where ABVC and BioLite will each receive 23 million shares of AIBL stock, potentially leading to ABVC having a controlling interest in AIBL.

10-Q filing | 7.2M shares outstanding

8-K filing: ABVC BioPharma, Inc. entered into a letter agreement with Lind Global Fund II LP, waiving certain defaults related to the Company's market capitalization, while Lind retains its conversion rights which could result in a substantial amount of common stock issued at a significant discount.

8-K filing: ABVC BioPharma, Inc. entered into a cooperation agreement with Zhonghui United Technology (Chengdu) Group Co., Ltd. to acquire 20% ownership of a property in Leshan, Sichuan, China, in exchange for 370,000 shares of ABVC's common stock at $20.0 per share. ($7.4M proceeds)

10-Q filing | 4.0M shares outstanding

8-K filing: ABVC BioPharma, Inc. closed a registered direct offering on July 31, 2023, issuing 300,000 shares of common stock and 200,000 pre-funded warrants to an institutional investor.

8-K filing: ABVC BioPharma, Inc. entered into a securities purchase agreement to sell 300,000 shares of common stock and 200,000 pre-funded warrants at $3.50 per share, for gross proceeds of $1,750,000. ($3.5M proceeds)

8-K filing: Stock split 1-for-10 | Outstanding: 33,075,775 → 3,308,074

S-1/A filing: This is an S-1/A filing for ABVC Biopharma, Inc. related to the offering of common stock issuable upon conversion of a note and underlying warrants.

S-1/A filing: This is an S-1/A filing for ABVC BioPharma, Inc. related to the offering of common stock by selling stockholders upon conversion of a note and exercise of warrants.

10-Q filing | 33.1M shares outstanding

S-1/A filing: S-1/A filing on 2023-05-10 regarding an offering of common stock by selling stockholders.

POS AM filing: This POS AM filing details an offering of up to 2,255,000 shares of common stock issuable upon the exercise of outstanding warrants from a previous offering.

POS AM filing: This POS AM filing relates to the offering of up to 3,400,187 shares of common stock by Selling Stockholders. The company will not receive any proceeds from the sales.

S-1 filing: The filing relates to an offering of up to $3,175,000 of shares of Common Stock issuable upon conversion of the Note, up to 5,291,667 shares of Common Stock underlying the Warrant and up to 211,667 shares of Common Stock underlying the PA Warrant by Selling Stockholders.

10-K filing | 31.7M shares outstanding

8-K filing: ABVC BioPharma, Inc. entered into a securities purchase agreement with Lind Global Fund II, LP to issue a secured, convertible note in the principal amount of $3,704,167 for a purchase price of $3,175,000, convertible into shares of the Company's common stock at $1.05 per share, and a common stock purchase warrant to purchase up to 5,291,667 shares of common stock at $1.05 per share.

10-Q filing | 32.6M shares outstanding

10-Q filing | 31.3M shares outstanding

POS AM filing: This POS AM filing relates to the offering of up to 4,575,923 shares of common stock by Selling Stockholders. The company will not receive any proceeds from the sale of these shares.

POS AM filing: This is a filing for securities offered upon exercise of outstanding warrants issued in August 2021 public offering.

8-K filing: ABVC BioPharma, Inc. closed a transaction on May 16, 2022, issuing 2,000,000 shares of common stock at $2.11 per share and warrants to purchase up to 2,000,000 shares to an institutional investor, with WallachBeth Capital LLC and ViewTrade Securities, Inc. acting as co-placement agents. ($4.22M proceeds)

10-Q filing | 29.7M shares outstanding

8-K filing: ABVC BioPharma, Inc. entered into a securities purchase agreement on May 11, 2022, for the offer and sale of 2,000,000 shares of common stock in a registered direct offering, along with warrants to purchase 2,000,000 shares. ($4.22M proceeds)

10-K filing | 30.3M shares outstanding

S-3/A filing: ABVC BioPharma, Inc. may from time to time sell common stock, preferred stock, warrants, or a combination of these securities for an aggregate offering price of up to $50,000,000.

10-Q filing | 26.9M shares outstanding

8-K filing: ABVC BioPharma, Inc. entered into a Joint Venture Agreement with Lucidaim Co., Ltd. and BioLite Japan K.K., transferring 54 ordinary shares of Biolite to Lucidaim for no consideration, resulting in Lucidaim owning 51% and ABVC owning 49% of Biolite's Ordinary Shares.

10-Q filing | 24.5M shares outstanding

S-1/A filing: ABVC Biopharma, Inc. proposes to issue and sell to the underwriters an aggregate of 1,000,000 Units, each Firm Unit consisting of one share of the Company's common stock, one Series A warrant to purchase one share of Common Stock and one Series B warrant to purchase one share of common stock; also an option to purchase up to an additional 150,000 shares of Common Stock, Series A warrants and Series B warrants.

S-1/A filing: This is an S-1/A filing for an offering of units, each consisting of one share of common stock, Series A warrants, and Series B warrants, with an assumed initial public offering price of $6.25 per unit, aiming to raise approximately $6,250,000 for funding clinical trials and general business purposes.

S-1/A filing: This S-1/A filing relates to an offering of units, each consisting of one share of common stock and warrants to purchase common stock.

S-1/A filing: S-1/A filing for offering of units, each consisting of one share of common stock, one Series A warrant, and one Series B warrant, at an assumed price of $6.25 per unit.

S-1/A filing: This S-1/A filing relates to an offering of Units, each consisting of one share of common stock and warrants to purchase common stock, with an over-allotment option for additional shares and warrants.

10-Q filing | 24.4M shares outstanding

POS AM filing: This prospectus relates to the resale of up to 4,575,923 shares of Common Stock of ABVC BioPharma, Inc. by the selling stockholders.

S-1 filing: This is a firm commitment underwritten public offering by ABVC Biopharma, Inc. of units, each consisting of one share of common stock, one Series A warrant, and one Series B warrant.

10-K filing | 24.4M shares outstanding

S-1/A filing: This prospectus relates to the resale of up to 4,575,923 shares of Common Stock by selling shareholders.

S-1 filing: This S-1 filing relates to the resale of up to 4,575,923 shares of Common Stock by selling shareholders.

10-Q filing | 19.5M shares outstanding

8-K filing: American BriVision (Holding) Corporation closed a securities purchase agreement with two non-U.S. investors, selling 1,111,112 shares of common stock and warrants to purchase 1,111,112 shares for $2,500,000 each, resulting in aggregate net proceeds of $5,000,000 for the Company. ($5.0M proceeds)

8-K filing: American BriVision (Holding) Corporation closed the transactions contemplated by the Exchange Agreements, issuing an aggregate of 795,735 shares of the Company's common stock and warrants to purchase 795,735 shares of Common Stock to certain U.S. and non-U.S. holders.

10-Q filing | 19.5M shares outstanding

10-Q filing | 19.5M shares outstanding

10-K filing | 19.5M shares outstanding

8-K filing: American BriVision (Holding) Corporation entered into exchange agreements with certain non-U.S. holders to exchange convertible promissory notes for 289,438 shares of common stock and warrants to purchase 289,438 shares of common stock.

8-K filing: American BriVision (Holding) Corporation entered into exchange agreements with certain holders of convertible promissory notes to exchange $941,584.07 in notes for 506,297 shares of common stock and warrants to purchase 506,297 shares of common stock.

RW filing: The company has withdrawn the registration statement.